Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
暂无分享,去创建一个
Jordi Rodon | Irene Braña | J. Baselga | G. Shapiro | E. Kwak | I. Braña | Cynthia Bedell | Coumaran Egile | Jose Baselga | C. Bedell | Geoffrey I Shapiro | Eunice L Kwak | G. Edelman | Shuchi S Pandya | Christian Scheffold | A Douglas Laird | Linh T Nguyen | Yi Xu | Gerald Edelman | C. Scheffold | S. Pandya | A. Laird | C. Egile | L. Nguyen | Yi Xu | J. Rodón
[1] E. Hirsch,et al. PI3K keeps the balance between metabolism and cancer. , 2012, Advances in biological regulation.
[2] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[3] Razelle Kurzrock,et al. A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[4] K. Okkenhaug,et al. The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ , 2008, Proceedings of the National Academy of Sciences.
[5] G. Hampton,et al. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma , 2013, Journal of Translational Medicine.
[6] A. Regev,et al. Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia , 2012, Clinical Cancer Research.
[7] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[8] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[9] J. Baselga,et al. Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. , 2013 .
[10] J. Berlin,et al. Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study. , 2013 .
[11] P. Dennis,et al. PTEN loss in the continuum of common cancers, rare syndromes and mouse models , 2011, Nature Reviews Cancer.
[12] J. Engelman,et al. The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Berlin,et al. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study , 2012 .
[14] John M. S. Bartlett,et al. PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer , 2013, PloS one.
[15] P. Warne,et al. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.
[16] L. Zhao,et al. Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.
[17] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[18] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Paradiso,et al. Preferential chemosensitization of PTEN‐mutated prostate cells by silencing the Akt kinase , 2007, The Prostate.
[20] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[21] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Levitzki,et al. Targeting the EGFR and the PKB pathway in cancer. , 2009, Current opinion in cell biology.
[23] Jie Qi,et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.
[24] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[25] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[26] Stephen L. Abrams,et al. Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response , 2012, Oncotarget.
[27] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.